Launch week offerEnds in00h00m00s

annual Promonthly Pro

Guillermo Ramil López

Has grant

Hospital de la Santa Creu i Sant Pau

Spain

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Spain

Recent Grants

Grant: Close

New strategies for measurable residual disease monitoring in acute myeloid leukemia: application of NGS and digital PCR

Open Date: 2024-01-01

Close Date: 2025-01-01

Articles (17)

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (2)

Josep Nomdedeu

Group leader

Hospital de la Santa Creu i Sant Pau

SPAIN

View details

ALBERT TUCA

Associate Professor. AQU accreditation

University of Barcelona

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Guillermo Ramil López

Research Interests

Make your next move.

Explore related searches

Recent Grants

Articles (17)

ASSESSMENT OF THE IPSS-M IN CHRONIC MYELOMONOCYTIC LEUKEMIA

Performance and clinical utility of Spanish germ line genetic testing criteria for hematologic neoplasms predisposition

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia

Bone marrow alterations and clonal hematopoiesis in germline ETV6 mutation carriers without hematologic malignancy

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease: Real-world data utilization from the ELN-david MRD international working group

Incidence and molecular underpinnings of donor-cell derived neoplasm among spanish transplantation centers

Performance and clinical utility of germline genetic testing criteria for predisposition to myeloid neoplasms in adults

Real-world insights into venetoclax and/or hypomethylating agent discontinuation in patients with Acute Myeloid Leukemia

Reticulocyte Count Interference at the Onset of Acute Myeloid Leukemia

Be aware of the X: <i>BCOR</i> mutations in myeloid neoplasms.

Association of Clonal Hematopoiesis and Dysgranulopoiesis with Germline ETV6 Carriers without Hematological Malignancies

Comparative Analysis of NGS and Digital PCR for Measurable Residual Disease Monitoring in Intensively Treated Acute Myeloid Leukemia Patients

Impact of Transfusion Dependency on Patients Diagnosed with Myelodysplastic Syndrome According to IPSS-M Risk Group

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

UBTF Tandem Duplications Define a Novel Subtype of Acute Myeloid Leukemia Associated with Younger Age, WT1 Mutations and HOXA9 Marked Overexpression

Collaborators (2)

Josep Nomdedeu

ALBERT TUCA

Make your next move.